Health Care Delivery

The authors, from RxCrossroads by McKesson, discuss the impact of copay accumulator and maximizer programs.

A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.

A new national study is highlighting disparities in morbidity and barriers to care that face patients with chronic obstructive pulmonary disease (COPD) living in in rural areas.

It is the first PD-1 inhibitor to be approved to be used as a monotherapy for the treatment of adult and pediatric patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).

Nearly 10,000 deaths from non–small-cell lung cancer (NSCLC) were likely delayed between 2014 to 2016, the researchers calculated.

New data estimates from the Global Burden of Disease Study published by The Lancet illustrate how rising rates of chronic disease and public health failures compounded over decades to worsen the coronavirus disease 2019 (COVID-19) pandemic.

Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Addressing coronavirus disease 2019 (COVID-19) means addressing racism, according to 2 experts in the latest episode of Managed Care Cast.

Younger age, poverty, recent drug use, depression, and unmet need for ancillary services were linked to lowered antiretroviral therapy (ART) adherence among HIV-positive Hispanic and Latino men who have sex with men (MSM).

Rebooting the immune system is an exciting approach, noted John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine, and co-director of the Rocky Mountain MS Center at Anschutz Medical Campus.

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.

Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.

Depression affects up to 17% of patients with rheumatoid arthritis, but not all patients are assessed for their mental well-being.

Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care

Two women are awarded the Nobel Prize in Chemistry for CRISPR; Eli Lilly partners with DexCom, Inc; the US arm of AstraZeneca’s coronavirus disease 2019 (COVID-19) vaccine trial remains halted.

Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, according to study results.

Telehealth claims peaked in June 2020, then eased off a bit in July. There were more telehealth claims in the Northeast than in other regions.

About 3 days after being airlifted to the hospital to be treated for symptoms stemming from coronavirus disease 2019 (COVID-19) infection, the president is returning to the White House.

Two neurologists discuss what is known and unknown in switching patients with migraine from one calcitonin gene-related peptide (CGRP) inhibitor to another.

Increasing at-home access to care and treatment options for spinal muscular atrophy (SMA) proved to be helpful during the coronavirus disease 2019 (COVID-19) pandemic, explained Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA.

Differences in long-term outcomes in patients with rheumatoid arthritis (RA) may because RA with and without autoantibodies are actually 2 distinct conditions.

A House panel found pharmaceutical companies exponentially increased drug prices to boost profits; CDC data show an increase in alcohol-related deaths, especially among women; 4 million more Americans enroll in Medicaid.

Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said.

Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.